A5004380336- Ocular Oncology and Treatments
- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Sarcoma Diagnosis and Treatment
- Neuroblastoma Research and Treatments
- Cancer Genomics and Diagnostics
- Bone health and treatments
- Immune cells in cancer
- Macrophage Migration Inhibitory Factor
- Immune Cell Function and Interaction
- Bone and Dental Protein Studies
- Oral and Maxillofacial Pathology
- Glioma Diagnosis and Treatment
- Cancer-related Molecular Pathways
- Cell death mechanisms and regulation
- Brain Metastases and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Cancer, Hypoxia, and Metabolism
- Head and Neck Surgical Oncology
Hospital Sant Joan de Déu Barcelona
2020-2025
Red de Investigación en Actividades Preventivas y Promoción de la Salud
2020-2025
Institut de Recerca Sant Joan de Déu
2020-2024
Abstract Purpose: Retinoblastoma is the most common intraocular malignancy in children. Although new chemotherapeutic approaches have improved ocular salvage rates, novel therapies are required for patients with refractory and metastatic disease. Chimeric antigen receptor (CAR) T cells targeting glypican-2 (GPC2) a potential therapeutic strategy. Experimental Design: GPC2 expression its regulation by E2F1 transcription factor were studied retinoblastoma patient samples cellular models. In...
We aimed to expand and refine the experimental models for pediatric-type diffuse high grade gliomas (pHGG) methods follow up disease progression in mouse pHGG xenografts. Using whole exome sequencing immunoassays we characterized primary cultures xenografts established at hospital SJD Barcelona. obtained tumor samples serial CSF from To assess progression, evaluated: (1) weight, (2) human cell counts brain paraffin sections, (3) DNA amount, quantified through droplet digital polymerase chain...
Abstract The goals of this work were to identify factors favoring patient‐derived xenograft (PDX) engraftment and study the association between PDX prognosis in pediatric patients with Ewing sarcoma, osteosarcoma, rhabdomyosarcoma. We used immunodeficient mice establish 30 subcutaneous from patient tumor biopsies, a successful rate 44%. Age greater than 12 years relapsed disease associated higher rate. Tumor type biopsy location did not associate engraftment. models retained histology...
Abstract The microenvironment of retinoblastoma, the solid malignancy developing retina, is immunosuppressive. To study interactions between tumor‐associated microglia/macrophages (TAMs) and tumor cells in retinoblastomas, we analyzed immunohistochemistry markers 23 patient samples characterized 105 secreted cytokines 11 retinoblastoma cell models culture. We detected profuse infiltration CD163 + protumoral M2‐like polarized TAMs eyes enucleated due to cancer progression. Previous treatment...
Abstract Fundoscopy is the standard method for diagnosis and follow‐up of intraocular retinoblastoma, but it sometimes insufficient to discern whether tumors are inactivated following treatments. In this work, we hypothesized that amount conserved nuclear DNA sequences in cell‐free (cfDNA) fraction aqueous humor (AH) might complement fundoscopy retinoblastoma follow‐up. To address our hypothesis, developed highly sensitive droplet digital polymerase chain reaction (ddPCR) methods quantify...
<p>Supplementary Figure 1. Expression of GPC2 and GD2 in retinoblastoma patient samples cell lines (see related main Fig. 1).</p>
<div>AbstractPurpose:<p>Retinoblastoma is the most common intraocular malignancy in children. Although new chemotherapeutic approaches have improved ocular salvage rates, novel therapies are required for patients with refractory and metastatic disease. Chimeric antigen receptor (CAR) T cells targeting glypican-2 (GPC2) a potential therapeutic strategy.</p>Experimental Design:<p>GPC2 expression its regulation by E2F1 transcription factor were studied retinoblastoma...
<div>AbstractPurpose:<p>Retinoblastoma is the most common intraocular malignancy in children. Although new chemotherapeutic approaches have improved ocular salvage rates, novel therapies are required for patients with refractory and metastatic disease. Chimeric antigen receptor (CAR) T cells targeting glypican-2 (GPC2) a potential therapeutic strategy.</p>Experimental Design:<p>GPC2 expression its regulation by E2F1 transcription factor were studied retinoblastoma...
<p>Supplementary Figure 3. Mouse retina expression of GPC2 and GD2, retinal CAR T-cell infiltration, systemic toxicities, antigen loss in the intraocular model (see related main Fig. 4).</p>
<p>Supplementary Figure 4. Mouse body weights and GPC2 expression in the brains of study endpoint mice included CNS efficacy (see related main Fig. 5).</p>
<p>Supplementary Figure 2. GPC2 CAR expression, activation, and polyfunctionality (see related main Fig. 3).</p>
<p>Supplementary Figure 4. Mouse body weights and GPC2 expression in the brains of study endpoint mice included CNS efficacy (see related main Fig. 5).</p>
<p>Supplementary Figure 3. Mouse retina expression of GPC2 and GD2, retinal CAR T-cell infiltration, systemic toxicities, antigen loss in the intraocular model (see related main Fig. 4).</p>
<p>Supplementary Figure 2. GPC2 CAR expression, activation, and polyfunctionality (see related main Fig. 3).</p>
<p>Supplementary Figure 1. Expression of GPC2 and GD2 in retinoblastoma patient samples cell lines (see related main Fig. 1).</p>